News Hub | News Direct

Turtle Wax Names Mexican-American Race Car Driver Daniel Suarez its Art of Car Care™ Line's First Brand Ambassador for Mexico

Turtle Wax

WHO: Rev up your engines and mark your calendars for an electrifying announcement! Mexican-American racing sensation Daniel Suarez has been named the first-ever Brand Ambassador for Turtle Wax's Art of Car Care™ line in Mexico. Get ready to witness his unparalleled energy and expertise in car care. WHAT: Witness the electrifying impact of Mexican-American race car driver Daniel Suarez as he takes on the role of the first-ever Brand Ambassador for Turtle Wax's Art of Car Care™ line in Mexico. Suarez's unparalleled energy and expertise in the automotive world will provide an exciting new dimension to the acclaimed brand, the perfect complement to the bold, disruptive nature of the Art of Car Care™ line. WHEN: Keep your engines revving as Daniel Suarez's Art of Car Care™ episode drops. It’s a season finale you don't want to miss! Click here to watch the first season on YouTube, with all episodes available on August 23, 2024. WHERE: Hold onto your seats because there's more excitement in store! Suarez will appear in the highly-anticipated season finale of the Art of Car Care™ YouTube series. In this must-see episode, he shares riveting insights into his lifelong journey with cars and the deep-rooted love that fuels his fervor for automotive restoration. WHY: Known for his stellar performance on the racetrack and unwavering passion for all things automotive. Off the track, Suarez brings boundless energy and passion to the world of car care. From his formative years spent in his father's restoration shop in Monterrey, Nuevo Leon, Mexico, to his current status as a star in the professional stock car racing circuit and countless restoration side projects, Suarez's connection to the automotive world is unparalleled. ABOUT TURTLE WAX® The Turtle Wax story started with the launch of the first-ever bottled car wax in 1944. More than 75 years later, the 'Most Innovative Brand in Car Care' is still capturing the attention of the auto appearance industry with a cross-category assortment of No. 1 selling products. With product distribution in more than 120 countries, the Turtle Wax brand resonates globally. Still, the brand's heart remains in its hometown of Chicago, where award-winning innovation is still developed. For an inside look at the brand's breakthrough product development process or how Turtle Wax supports car culture worldwide, visit TurtleWax.com. Contact Details Glenda Vaquerano glenda@theidagency.com Company Website http://turtlewax.com/

August 21, 2024 06:07 AM Pacific Daylight Time

Image

Wolfpack: The Financial Services Company Designed For Millennial And Gen Z Investors

Benzinga

By Anthony Termini, Benzinga When George Parthimos’s teenage children started asking him about the stock market, he did what many parents would do – especially if they’re former technology executives. He created a self-directed trading platform for beginning and inexperienced investors. That was the genesis of Wolfpack Financial. A Proprietary Buy-Now-Pay-Later Approach To Trading, Lending And Investment Education Wolfpack, incorporated in Delaware and headquartered in New York, offers a suite of financial products and services through a native mobile app designed to help investors build sustained investments. Wolfpack is not a day trading platform. It empowers new and inexperienced investors to discover opportunities, make trades easily and grow their overall investment portfolios over time. The product provides a powerful mobile-first investment and social platform that includes lending features using technology familiar to millennial and Gen Z consumers. Wolfpack’s goal is to help give people control over their finances and the opportunity to build generational wealth. Its suite of products includes a short-term point-of-sale lending product. The company has innovated traditional stock market lending products by creating a patent pending product it refers to as a “Booster Loan.” Wolfpack says that Booster Loans are the only fully collateralized Buy Now Pay Later lending product available from a financial institution. Wolfpack positions the Booster Loan as a better alternative to personal loans, credit cards and traditional margin lending, all of which come with high interest rates and potentially higher credit and investment risks. Booster Loans extend credit to investors for the purchase of common stocks or exchange-traded funds (ETF). Investors repay these loans over a fixed 10-week repayment schedule. Wolfpack expects Booster Loans to be rolled out in the fourth quarter of 2024. To further appeal to consumers who are new to investing or have little experience, Wolfpack makes it possible to open an account with a minimum of $5. In addition, it offers up to $50 in rewards on new accounts with a minimum $100 deposit that meet certain requirements. It is important to note that consumers who download the mobile app and fund an account automatically receive pre-approval for up to $2,000 in Booster Loans. When launched, they will also receive priority access to Booster Loans. The penalty-free Wolfpack app is designed to help investors discover the financial benefits of stocks and ETFs. It lets investors buy these securities from as little as $5.00 per trade. The service includes fractional share trading and charges zero commissions. Importantly, Wolfpack allows users to tailor screens that fit their personal investing criteria and matches the investor with the stocks and ETFs that meet those parameters. Parthimos, who is Wolfpack’s founder and CEO, says that the app is “designed to be a one-on-one relationship between the market and the individual.” Originally created with Parthimos’s now-adult children in mind, he says that the app “allows for the individual to set in a suite of filtering criteria that they are looking for that is very specific and custom to them.” The platform includes personal finance education modules and descriptions of common investment terminology. Wolfpack’s premium data services alert users with trade signals and trend data based on their specific investment criteria. Wolfpack’s Business Strategy Wolfpack’s focus on millennials and Gen Z investors is grounded in data. As Charles Schwab’s 2024 Modern Wealth Survey points out, more than 40% of them invest in stocks. Wolfpack says they are targeting a total addressable market of more than 134 million consumers. The company notes that millennial workers in the gig economy identify themselves as entrepreneurs rather than freelancers and are more likely to use a self-directed trading app than a traditional broker to manage their financial affairs. The company’s retail strategy involves launching and promoting the Wolfpack app to its target demographic through a number of social media channels. The customer acquisition strategy involves maximizing top-of-funnel app downloads, converting registered users to brokerage accounts, increasing engagement to drive monthly active users and ultimately signing up Booster Loans at point-of-sale. Wolfpack reports that it currently has one of the lowest customer acquisition costs in the industry. The company is also pursuing a B2B market strategy. Wolfpack’s focus on business customers involves licensing its proprietary app and services – namely the Booster Loan opportunity – through strategic partnerships with banks, broker-dealers and securities clearing houses. The company says it has determined that more than 90% of US banks and broker-dealers don’t have a securities trading solution for their customers, and this can lead to customer attrition in favor of companies that provide brokerage services. By licensing Wolfpack’s technology platform, these institutions create a stickiness that can reverse outflows, add new customers and grow their assets under management by offering new services. The company estimates that the combined consumer and enterprise opportunity in the margin lending business alone exceeds $600 billion. Other key revenue streams include transaction fees and monthly premium subscription services. For enterprise customers, revenues will be derived from platform licensing fees, premium subscription services, Booster Loan portfolio management fees and transaction fees. Information about Wolfpack’s business fundamentals is available on the Wefunder website. Investors interested in the rewards and priority access opportunities offered by Wolfpack should visit the company’s website. Featured photo by sergeitokmakov from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:45 AM Eastern Daylight Time

Image

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Inks Key Partnership, Advances Chip Development, Explores AI Datacenter Expansion

Benzinga

By Gerelyn Terzo, Benzinga Bitcoin investors showed their resilience when the flagship cryptocurrency got caught up in recent broader market volatility that sent the BTC price below $60,000. Investors rotated out of Big Tech recently amid economic and market uncertainty, but they may still have their eye on the AI and data center prize, which could bode well for Bitcoin miners and other companies operating in this arena. Institutional investors reportedly bought the Bitcoin dip as $245 million in inflows moved into spot Bitcoin ETFs during the summer doldrums. While Bitcoin ETFs only recently made their debut, many investors seem to have proven their willingness to endure market swings. One company strategically positioning itself in the Bitcoin space is Bitdeer Technologies Group (NASDAQ: BTDR), which continues to advance its roadmap in 2024. Bitdeer has published its production and operations update for July, during which time it hit several key milestones. Among the highlights was the fact that Bitdeer mined 181 Bitcoins compared with 179 in June. Additionally, the company reports that it solidified a key engagement with Tier 3 and 4 data center consultant TLM Group, inched closer to the monetization of its power portfolio and proved to be on pace for the deployment of its Bitcoin self-mining ASIC chips. Investors looking to gain exposure to Bitcoin but not prepared to directly buy into the asset class may want to investigate Bitdeer’s stock, which they can learn more about here. Bitdeer’s Computational Power On The Rise In July, Bitdeer’s total hashrate – a reflection of the computational power a network possesses to mine BTC – under management was 21.2, up from 20.6 in the same month in 2023. The company is targeting the expansion of its hash rate by 3.4EH/s by year-end, growth that will be fueled by the manufacturing of its SEALMINER A1 rigs. In July, mass production of Bitdeer’s new mining chip, dubbed SEAL01, the powerhouse for the SEALMINER A1 mining rig series, remained on track while the company implemented air cooling and hydro cooling capabilities. Bitdeer is preparing for mass production of its second-generation chip, SEAL02, by year-end 2024. Meanwhile, R&D activities on its third-generation chip, dubbed SEAL03, are also underway. High-Performance Computing And AI Bitdeer’s AI cloud services are powered by technology from AI leader Nvidia (NASDAQ: NVDA), the systems for which attained 100% utilization in July. The company has plans to expand its AI cloud footprint to seize opportunities as they present themselves while remaining disciplined on capital expenditures. With TLM Group on board, which is out front for high-performance computing (HPC) and AI datacenter engineering and construction, the company can harness the consultant’s expertise to evaluate the suitability of its current sites while collaborating with them on a broader datacenter strategy. Bitdeer says this partnership may involve co-locations, joint ventures and other ways to monetize the high-demand HPC and AI segments. Bitdeer’s Global Datacenter Expansion Datacenters make up the key infrastructure where AI magic takes place, and Bitdeer oversees several facilities strategically located around the world, including Rockdale, Texas, Tydal, Norway, Massillon, Ohio and Jigmeling, Bhutan, the construction of which progressed in July. In July, the Phase 1 and Phase 2o expansions of Bitdeer’s Norway datacenter remained on pact to deliver 40 MW in Q4 2024 and 135 MW by mid-2025. In Bhutan, Bitdeer is targeting the completion of a 500MW substation by Q1 2025. An upgrade of the Texas mining datacenter to hydro cooling is underway and should be complete by year-end 2024. In Ohio, Bitdeer said the 221MW project is proceeding as expected in the design and long lead time equipment procurement stage. Bitdeer plans to deploy 3.4 EH/s of first-generation Bitdeer SEALMINERs into its Texas and Norwegian sites in Q4 2024, catapulting its total proprietary hashrate to 11.8 EH/s. Bitdeer’s Year-End Push With roots in Bitcoin mining that date back to 2013, Bitdeer has been among early movers in this market, including ASIC technology, which is used by the toughest mining rigs on the planet. As the company gears up for the final stretch of 2024, Bitdeer has no plans of slowing down and will participate in several events. Among them is Rosenblatt’s virtual tech summit, which will be held in August and will focus on “The Age of AI.” In September, Bitdeer will be featured at H.C. Wainwright’s global investment conference in New York before heading to Miami for the Canto Crypto conference in November, which will similarly focus on AI infrastructure. Investors considering becoming part of the Bitdeer growth story cite the company’s participation in the Bitcoin ASIC chip mining, AI/HPC and data center story. With a consensus analyst rating of “ buy,” Bitdeer shareholders may be in good company. Featured photo by satheeshsankaran on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:35 AM Eastern Daylight Time

Image

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Benzinga

By Meg Flippin, Benzinga You can’t wing it when it comes to diabetes. Everything you eat and drink, the amount of physical activity you engage in and the medicines you take must be monitored closely. Keeping your blood glucose level within its target range is vital in preventing other medical issues. But managing diabetes can be cumbersome and intrusive. The main way of tracking glucose in your blood is via a glucose meter which requires you to prick your finger several times a day to get a sample of your blood. These meters provide blood glucose readings – which is considered the most accurate form of glucose monitoring – however testing must be done often and even then users can miss highs and lows in their glucose and the direction in which their glucose is changing. This type of monitoring is also a constant reminder of the disease. A More Modern Approach Continuous glucose monitoring (CGM) offers a better alternative. With it, your glucose level is monitored automatically through a device worn on the body 24 hours a day. It enables you to review your glucose levels to make well-informed decisions and adjust your behavior on a continual basis. These devices also enable people with diabetes to review how their glucose levels change over hours, days, weeks and months. Using a CGM device can help patients better manage glucose levels, reduce the number of low glucose events and decrease or eliminate the number of finger pricks. If your glucose rises or drops beyond a certain threshold, you’ll be alerted. The convenience is a big reason why the market for CGM devices is large and growing. In 2024 it is forecast to hit $16.2 billion and reach $44.6 billion by 2034, growing at a CAGR of 10.3%. Driving the demand is a need among patients to find a more convenient way to manage this chronic disease. After all, life doesn’t have to stop just because you have been diagnosed with diabetes. Diabetes is a disease that's growing in the U.S. and around the globe, impacting people of all ages. The total number of people around the globe who suffer from diabetes is projected to reach 643 million by 2030 and soar to 783 million by 2045. While adults are the most likely to be diagnosed with diabetes, it impacts children as well at a growing rate. Not Every CGM Device Is The Same But when it comes to CGM, not all devices are created equally. The duration that the monitoring lasts, the placement of the device, the type of glucose being tested and how often data is received differ from one manufacturer to the next. Take DexCom Inc. (NASDAQ: DXCM) for starters. Its CGM device consists of sensors worn under the skin that must be reapplied every 10 to 15 days, depending on the system, and which monitor glucose data every five minutes. The results are accurate but they measure interstitial glucose, which can lag 10 to 15 minutes behind blood glucose, so there is a delay versus blood glucose readings. Meanwhile, FreeStyle Libre by Abbott Laboratories (NYSE: ABT) is a CGM device that also monitors glucose from interstitial fluids just underneath the skin rather than glucose in the blood. It uses a sensor that is worn on the back of the arm and measures glucose every minute versus every five minutes. The sensor has to be reapplied every 14 or 15 days, depending on the system. Eversense, a CGM device made by Senseonics Holdings Inc. (NYSE: SENS), is another type that works by implanting a small sensor under your skin, along with a transmitter worn on top of the skin. It measures the glucose in interstitial fluids every five minutes and the sensor works for up to 180 days before it needs to be swapped out. While all these devices are much easier to use than multiple finger pricks a day, they do require some intervention after a period of time and don’t measure glucose in the blood. And, they each require an on-body wearable, so there is the possibility of skin irritation and sensors falling off early or during physical activities like swimming or hot yoga. Additionally, having a wearable on the body reduces the amount of discretion that some people with diabetes desire. A Potentially Better Way Glucotrack, Inc. (NASDAQ: GCTK) is different. The Rutherford, New Jersey, medical technology company focused on the design, development and commercialization of novel technologies for people with diabetes has developed a Continuous Blood Glucose Monitor (CBGM) that aims to overcome the challenges of today’s CGM, including delays due to the interstitial lag, the need for frequent sensor changes and concerns regarding comfort and wearability. Unlike the others on the market, Glucotrack's device measures glucose in the blood. Because Glucotrack’s implantable CBGM measures glucose in the blood, it doesn’t have the lag time associated with subcutaneous sensors that measure glucose in interstitial fluid. The ability to directly measure blood glucose in real-time and on a continuous basis enables a less burdensome approach to glucose monitoring for extended periods of time. Additionally, with no on body wearable, the CBGM offers increased discretion to the user, making it potentially less intrusive to daily living. What’s more, Glucotrack’s implant can last up to three years, compared to months for the other CGM devices on the market. Patients don’t have to worry about sticking an adhesive to their body or be concerned about it falling off during physical activity. And, with minimal calibration required, the CBGM eliminates the hassle and discomfort of a wearable that requires frequent replacement. Monitoring glucose and thus living with diabetes can become easier with Glucotrack. Proof Through Studies Glucotrack has data to back up its claim. It recently completed a second long-term preclinical study for its CBGM device, which showed a Mean Absolute Relative Difference (MARD) of 4.7% at day 90, which is considered highly accurate for a continuous glucose monitor, the company reports. MARD is a key metric used to assess the accuracy of glucose monitoring devices, measuring the average difference between the CBGM device’s measurement and a reference measurement, most often obtained via capillary blood glucose. Lower values indicate better performance, said Glucotrack. The company said the 90-day preclinical study, which included a larger number of animal subjects and a longer duration than the initial 60-day study announced earlier this year, further validates the CBGM sustained accuracy and performance. “We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials” stated Paul Goode, Ph.D., president and CEO of Glucotrack. “Our CBGM’s ability to continuously measure blood glucose for three years with accuracy, minimal calibration and without a wearable represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution.” The company presented preclinical animal data and longevity data at the 84th Scientific Sessions of the American Diabetes Association (ADA) held Jun. 21-24, 2024 in Orlando, Florida. The company also provided market research data showing acceptability of the CBGM with a large number of people with diabetes at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference held Aug. 9-12, 2024, in New Orleans, Louisiana. Diabetes is a chronic disease that’s poised to impact hundreds of millions of people around the globe. Managing the disease today is cumbersome and intrusive, even with the technological advances that the current generation of CGM devices have brought. Glucotrack wants to change that and believes its device is the answer. If preclinical test results are any indication, the company may be on to something that could be life-transforming for people with diabetes. Featured photo by Sweet Life on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:30 AM Eastern Daylight Time

Image

Airship AI (NASDAQ: AISP) Marks Six Months On The NASDAQ: Russell 2000 Inclusion, Company Projects Triple-Digit Growth For 2024

Benzinga

By James Blacker, Benzinga Redmond, Washington-based artificial intelligence company Airship AI (NASDAQ: AISP) seems to have quickly made its mark in the AI-driven surveillance technology space since its bourse debut six months ago. Specializing in synthesizing vast amounts of data from surveillance cameras and sensors, the company uses AI to provide real-time actionable insights for its customers across a range of sectors, including law enforcement, defense, logistics and retail. In a recent interview with Benzinga, Airship AI President Paul Allen shared the latest updates from the company. Public Offering And Q2 Results Airship AI was founded in 2006 but only debuted on the NASDAQ in December 2023 through a special purpose acquisition company (SPAC). As Allen explained, the company’s decision to go public via a SPAC rather than an IPO was driven by a need for financial transparency, particularly in securing large government contracts. Having the backing of Wall Street gives Airship AI a competitive edge against large established defense contractors, as it reassures potential clients that the company has the financial stability to deliver on large-scale projects. The decision to go public appears to be paying off, with Airship AI’s latest financial report showing its growth over the second quarter. The company reported net revenues of $6.4 million, a gross profit of $4.5 million, a gross margin of 70% and a positive operating income. Allen noted that it has made significant progress toward its target of achieving triple-digit year-over-year revenue growth and being cash flow positive. Russell 2000 Inclusion: A Key Milestone Airship AI announced in July that it has been added to the Russell 2000 index, a benchmark for small-cap companies in the U.S. This achievement is a testament to its growth potential and a signal of confidence in the company’s future, with Allen pointing to its project pipeline and current opportunities as reasons for this confidence. While its shareholder base comprises mostly retail investors at present, the company’s inclusion in the Russell 2000 is expected to widen its exposure to institutional investors, which could open avenues for more significant investment. Harnessing AI For Real-World Impact The transformative potential of AI has been one of the main stories of the market recently, and Airship AI is using this technology to address some of the biggest challenges in safety and security. Applying advanced AI techniques to video data management, the company focuses on computer vision, object edge detection and real-time data analysis to enable its clients to make fast decisions in high-stakes situations. For example, Airship AI’s technology can be used to track a suspect’s movements, track packages on conveyor belts, or monitor public areas for unusual activity. Airship AI’s platform could even predict potential problems before they occur, offering its clients an invaluable level of foresight. Recent Contracts Airship AI has already attracted several high-profile clients, including awards from commercial and government entities. Most recently, the company announced on 25 June that it has been awarded a contract extension within the Department of Justice, which uses Airship AI’s Acropolis Enterprise Sensor Management video and data management platform to investigate and counter threats to national security. Also in June, the company announced a six-figure contract with a separate DOJ agency for its Acropolis platform. In the same month, Airship AI announced another six-figure contract with a Fortune 100 company in the transportation and e-commerce sector. The company will use the Acropolis platform to support operational and physical security requirements. Looking Ahead Allen highlighted Airship AI’s recent participation in the NASDAQ closing bell ceremony in May as a symbolic moment for the company, serving as a celebration of its first few months as a public company, and of the hard work and dedication it took to bring the company to this point. The company sees a big demand for its technology, with a market that is projected to grow to over $40 billion by 2030. With its recent financial performance exhibiting growth and its robust pipeline of projects, Airship AI seems well-positioned to capitalize on the growing demand for AI-driven surveillance and data management solutions. To find out more about Airship AI, visit its website. Read More Airship AI Makes Its Debut On The Nasdaq After Completing Merger With BYTE Acquisition Corp. Airship AI Awarded Contract With DOJ Agency, Marking Second Big Government Contract Win Since December IPO Featured photo by PhotoMIX Company on Pexels. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:15 AM Eastern Daylight Time

Image

News Release

The Future of Medicine: Key Biotech Stocks to Watch

OSTX ATNM PBYI CRBP

In today's rapidly advancing healthcare landscape, biotech companies are playing a crucial role in addressing some of the most challenging medical conditions. With a focus on innovation and precision, these companies are developing next-generation treatments and therapies that offer new hope for patients and present compelling opportunities for investors. Unlike many traditional sectors, biotech operates at the cutting edge of science and technology, often driving significant progress in areas such as targeted therapies, immunotherapies, and genetic research. As these companies push forward with their groundbreaking work, they not only stand to revolutionize patient care but also present promising prospects for those looking to invest in the future of medicine. Let’s take a closer look at four biotech companies making waves in the industry. OS Therapies, Inc. (NYSE-A: OSTX) OS Therapies, Inc. (NYSE-A: OSTX) is carving out a unique position in the oncology landscape with its innovative approaches to treating cancer. The company, still in its clinical stage, focuses on developing therapies for osteosarcoma and other solid tumors. Their flagship product, OST-HER2, utilizes a novel immunotherapy platform that leverages the immune-boosting properties of Listeria bacteria to target the HER2 protein—a key player in several cancers. The company's pipeline includes OST-HER2, an immunotherapy currently in a Phase 2b trial targeting resected, recurrent osteosarcoma. With the trial fully enrolled and results expected in the fourth quarter of 2024, investors are keenly awaiting data that could significantly impact the stock’s trajectory. OST-HER2 has already garnered notable designations such as Fast-Track, Orphan Drug, and Rare Pediatric Disease from the FDA, underscoring its potential to address unmet medical needs. In addition to OST-HER2, OSTX is advancing its tunable Antibody Drug Conjugate (tADC) platform. This next-generation technology employs pH-sensitive silicon-based linkers, known as SiLinkers, designed to deliver multiple therapeutic agents directly to tumors, minimizing harm to healthy cells. Early preclinical data from this platform shows promise, positioning OS Therapies as a company with innovative solutions that could transform cancer treatment. Recent milestones further highlight the company’s growth potential. OSTX successfully raised $6.4 million in its initial public offering (IPO) on July 31, 2024. This funding not only bolsters their financial position but also supports ongoing and upcoming clinical trials. Additionally, the company has entered into Johnson & Johnson Innovation – JLABS, which could enhance its development capabilities and expand its research network. Financially, OSTX has made significant strides. The conversion of outstanding preferred shares and debt into equity, alongside the successful IPO, positions OS Therapies with a solid cash runway extending into mid-2025. This financial stability is critical as they approach key clinical milestones and seek further regulatory approvals. On August 2, 2024, OS Therapies announced the formation of a Patient Advocacy Advisory Board (PAAB) dedicated to its osteosarcoma program. The PAAB, composed of key figures from the osteosarcoma community, including Miriam Cohen (Osteosarcoma Collaborative) and Mac Tichenor (Osteosarcoma Institute), will provide valuable insights and feedback as the company seeks regulatory approvals for OST-HER2. This board will meet quarterly to review clinical progress and guide discussions with the FDA regarding a potential Biologics License Authorization (BLA). Additionally, on August 6, 2024, OS Therapies introduced its Scientific and Medical Advisory Board (SMAB). This board includes leading experts in osteosarcoma from institutions such as Texas Children’s Hospital and the Cleveland Clinic. The SMAB will support the company in evaluating OST-HER2’s safety and efficacy compared to current standards of care, playing a crucial role in the company’s regulatory strategy and potential BLA submission. OS Therapies’ approach to addressing significant cancer challenges through its innovative platforms presents an intriguing opportunity for investors. With strong initial results, a promising pipeline, and a strategic partnership with JLABS, the company is well-positioned for future growth. For those looking to invest in a company at the forefront of cancer immunotherapy and antibody drug conjugates, OSTX offers a compelling proposition. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) CRBP is making notable strides in oncology with its innovative approach to addressing serious diseases. The company's diversified pipeline includes CRB-701, CRB-601, and CRB-913, each with unique mechanisms and promising potential. Corbus’ lead asset, CRB-701, is a next-generation antibody drug conjugate (ADC) targeting Nectin-4. Recently presented at the American Society of Clinical Oncology (ASCO) Annual Conference, the Phase 1 trial results have been promising. The study, conducted with CSPC Pharmaceuticals Group, is assessing CRB-701's safety and efficacy across multiple doses. Data through April 2024 reveals a 44% overall response rate and a 78% disease control rate in metastatic urothelial cancer, and a 43% ORR and 86% DCR in cervical cancer. The drug has been well tolerated, with manageable side effects including a few cases of skin rash and peripheral neuropathy, and no dose-limiting toxicities observed up to 4.5 mg/kg.. For the quarter ending June 30, 2024, Corbus reported a net loss of approximately $10.0 million, an increase from the previous year. This rise in loss is attributed to increased clinical trial costs for CRB-701 and drug manufacturing costs for CRB-913. The company ended the quarter with $147 million in cash, which, combined with recent fundraising, is expected to sustain operations through Q3 2027. Corbus also appointed Winston Kung to its Board of Directors as of August 16, 2024. Kung’s extensive experience in both the pharmaceutical industry and investment banking is anticipated to provide valuable insights and guidance as Corbus advances its pipeline. The company also announced the resignation of Avery “Chip” Catlin from the Board, after over ten years of service. Corbus Pharmaceuticals is advancing through significant clinical and corporate milestones. The encouraging data for CRB-701 and the progress in other pipeline assets position the company for potential growth. Continued development and forthcoming data releases will be crucial in determining the long-term impact of these promising therapies. Puma Biotechnology, Inc. (NASDAQ: PBYI) Puma Biotechnology is dedicated to advancing cancer treatment, with a focus on its lead drug, NERLYNX. Approved for HER2-positive breast cancer, NERLYNX has faced fluctuating sales performance. In Q2 2024, the drug generated $44.4 million in revenue, a 14% decrease from the previous year, but still managed to beat analyst expectations despite a sequential decline of 24.2%. The product’s total prescriptions rose by 3% sequentially but fell 14% year-over-year. In addition to NERLYNX, Puma is developing alisertib, an aurora kinase A inhibitor. This drug, licensed from Takeda in 2022, is being evaluated in several trials. The Phase I/Ib study presented at the 2024 ASCO Annual Meeting demonstrated alisertib’s potential when combined with osimertinib for treating osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC). The study showed an 81% disease control rate and a median progression-free survival of 5.5 months. Notably, alisertib was more effective in patients with TP53 wild-type mutations, prompting Puma to adjust the trial focus accordingly. PBYI reported a net loss of $4.53 million for Q2 2024, a stark contrast to the profit of the same quarter last year. The drop in revenue and increased operating costs have been concerns, though the company’s revenues from NERLYNX and royalties met expectations. Looking ahead, Puma’s pipeline, particularly the alisertib studies, could be pivotal in shaping its future performance. With trials like ALISCA-Lung1 for small cell lung cancer and the upcoming ALISCA-Breast1 study, Puma aims to address significant gaps in cancer treatment. While current financials reflect challenges, the potential breakthroughs in its pipeline offer a promising outlook for long-term growth. Actinium Pharmaceuticals Inc. (NYSE-A: ATNM) ATNM focuses on targeted radiotherapies for oncology patients who have not responded to conventional treatments. Its primary products, Iomab-B and Actimab-A, are aimed at treating relapsed and refractory acute myeloid leukemia (AML), offering substantial growth potential if the company’s clinical trials continue to yield positive results. The company's most advanced candidate, Iomab-B, is in a Phase 3 SIERRA trial for AML patients undergoing bone marrow transplants. Despite a setback regarding its Biologics License Application (BLA), where the FDA requested an additional randomized trial, Iomab-B has shown promising results. The SIERRA trial met its primary endpoint of durable complete remission (dCR) with a p-value of less than 0.0001. This success places Actinium in a strong position, though further validation through additional trials will be key to unlocking its full market potential. Actimab-A, another late-stage candidate, is being tested as a targeted radiotherapy both as a single agent and in combination with other therapies for AML. These ongoing trials could drive stock performance, especially as the company expands its reach into various cancer therapies. Additionally, Iomab-ACT, a newer agent, shows promise in the growing gene and cell therapy space. The targeted radiotherapy conditioning approach of Iomab-ACT could revolutionize how treatments like CAR-T and gene therapies are delivered. The CAR-T market, currently valued at over $3.5 billion in annual revenue, is projected to grow at a compound annual growth rate of 11%. If Iomab-ACT proves successful, it could capture a significant portion of this expanding market, potentially contributing blockbuster-level revenue by 2030. Actinium’s intellectual property portfolio supports this potential, with patent protection for Iomab-B and Iomab-ACT extending until 2040. The company’s ability to further develop these products, particularly in collaboration with institutions like Columbia University, presents a compelling investment case as it seeks to expand into high-demand areas like sickle cell disease and stem cell therapies. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OS Therapies Inc. to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

August 21, 2024 05:00 AM Eastern Daylight Time

Svenska lagar och regler - en inblick & rapport

AM Europe

Sveriges spellagstiftning genomgick en betydande förändring 2019 med införandet av en ny spellag. Syftet med reformen var att öka konsumentskyddet och kontrollera den svenska spelmarknaden. En direkt konsekvens av detta blev en striktare reglering av utländska casinon som riktar sig till svenska spelare. Utländska Casinon och Svensk Lag Innan 2019 var det relativt fritt fram för utländska casinon att verka på den svenska marknaden. Men med den nya spellagen är det endast casinon med svensk licens som får rikta sig till svenska spelare. Detta innebär att utländska casinon utan svensk licens inte längre får marknadsföra sig till svenska spelare eller erbjuda sina tjänster till dem. Vad betyder detta för svenska spelare? Begränsat utbud: Spelare har ett mindre utbud av casinon att välja mellan. Ökad säkerhet: Spelare som väljer ett svenskt licensierat casino kan känna sig säkrare då dessa casinon följer strikta regler och krav. Skatter: Vinster från spel på svenska casinon beskattas inte, medan vinster från spel på utländska casinon kan vara skattepliktiga. Spelinspektionen – Tillsynsmyndigheten Spelinspektionen är den svenska myndighet som ansvarar för att övervaka och kontrollera spelmarknaden. De har till uppgift att se till att spelbolag följer gällande lagar och regler, samt att skydda spelare från oärliga aktörer. Spelinspektionen har verktyg för att blockera olagliga casinon och kan även utdela sanktioner till bolag som bryter mot reglerna. Läs mer här: Utländska Casino NewsDirect Konsumentskydd och Ansvarigt Spelande Den nya spellagen har också infört skärpta krav på ansvarsfullt spelande. Casinon måste erbjuda verktyg för spelare att sätta gränser för sina spelande, och det finns även stödlinjer för spelberoende. Det är viktigt att komma ihåg att spel alltid innebär en risk. Det är därför viktigt att spela ansvarsfullt och sätta upp gränser för sig själv. Sammanfattning Sveriges spellagstiftning har blivit betydligt striktare för att skydda spelare och kontrollera spelmarknaden. Även om det innebär begränsningar för spelare, så ökar det också säkerheten och skapar en rättvisare spelmiljö. Det är viktigt att alltid välja ett svenskt licensierat casino för att vara säker på att spela på laglig grund och kunna ta del av konsumentskyddet. Viktigt att notera: Denna artikel är en allmän översikt och ersätter inte juridisk rådgivning. För mer detaljerad information rekommenderas att kontakta Spelinspektionen eller en jurist. Nyckelord: svensk spellagstiftning, utländska casinon, Spelinspektionen, ansvarsfullt spelande, konsumentskydd. Resurser Spelpaus.se spelinspektionen.se Stödlinjen.se Contact Details Spiru Borg +356 2735 7227 Spiru.borg@casinolistingmedia.com

August 20, 2024 11:00 PM Eastern Daylight Time

Image

Federated Indians of Graton Rancheria Supports California Governor Newsom’s Call to Halt Tribal Gaming Projects That Are Contrary to U.S. Department of Interior Precedent

Federated Indians of Graton Rancheria

California Governor Gavin Newsom’s Office urged the Department of the Interior not to move forward with new casino projects proposed by the Koi Nation of Northern California and the Scotts Valley Band of Pomo Indians at locations outside of their aboriginal homelands. In a letter to Assistant Secretary Bryan Newland, the Governor’s Office notes that both projects are far outside the aboriginal territory of the Koi Nation and the Scotts Valley Band and the Department of the Interior has failed to consider reasonable alternative locations within their Lake County homelands. The Governor’s Office also expressed concern that the Department of the Interior could stretch the limits of what is allowed under the Indian Gaming Regulatory Act to move these proposed casino projects forward, sidestepping the state and ignoring the concerns of other tribes and local communities. “ The Federated Indians of Graton Rancheria appreciates Governor Newsom’s support in protecting tribal sovereignty against Interior’s unexplained rush to move these projects forward while ignoring the concerns of local tribes,” said Federated Indians of Graton Rancheria Chairman Greg Sarris. “We have repeatedly explained to Interior that these projects will have devastating impacts to the rights and cultural resources of our Tribe and others in whose ancestral territory these prospective projects are located. Interior Secretary Deb Haaland has ultimate responsibility for these decisions and needs to ensure that Interior is working to protect the interests of all tribes.” *** About the Federated Indians of Graton Rancheria Graton Rancheria is a federally recognized Indian tribe comprised of Coast Miwok and Southern Pomo Indians. Legislation restoring federal recognition to the Federated Indians of Graton Rancheria was signed into law in December 2000. Tribal lands are located in Rohnert Park, Sonoma County, CA. For more information, visit www.gratonrancheria.com. # # # Contact Details Landis Communications Inc. Brianne Miller +1 650-575-7727 graton@landispr.com Company Website https://gratonrancheria.com/

August 20, 2024 04:48 PM Pacific Daylight Time

Andrew Klein, M.D. named UNOS Chief Medical Officer

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) announced today that it selected Andrew S. Klein M.D., M.B.A., F.A.C.S. as Chief Medical Officer. “Dr. Klein has long been one of the most respected transplant surgeons and clinical researchers in the country,” said UNOS CEO Maureen McBride. As Chief Medical Officer, Dr. Klein will serve as an expert medical and clinical resource to other UNOS staff, the organ donation and transplant community, and the public. He will assist UNOS staff with research projects and publications and provide medical and clinical perspectives in UNOS corporate initiatives. “During his 35 years in clinical transplantation, Dr. Klein led transformational culture change and leads with an emphasis on inclusivity, engagement, transparency, and communication – the type of leadership the organ donation and transplant community needs during this time of modernization of the nation’s transplant system. Dr. Klein’s expertise will support UNOS’ continued growth as a global leader in donation, transplant, and health.” Dr. Klein was the founding Director of the Johns Hopkins Comprehensive Transplant Center from 1996 – 2003 and of Cedars-Sinai Comprehensive Transplant Center from 2004 to 2022. Honors include Clinician Scientist and Distinguished Alumnus awards from The Johns Hopkins University, Healthcare Visionary Award from the American Liver Foundation, and most recently, induction into the Johns Hopkins Society of Scholars. Dr. Klein has a long history of volunteer leadership with the Organ Procurement and Transplantation Network and many professional societies including the American Society of Transplant Surgeons, American Association for the Study of Liver Diseases, and the International College of Surgeons. Dr. Klein received his undergraduate degree from Duke University and his M.D. and M.B.A. degrees from The Johns Hopkins University and completed fellowships at Harvard University and the David Geffen School of Medicine at UCLA. About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

August 20, 2024 03:30 PM Eastern Daylight Time

Image

All Industries

Turtle Wax Names Mexican-American Race Car Driver Daniel Suarez its Art of Car Care™ Line's First Brand Ambassador for Mexico

Wolfpack: The Financial Services Company Designed For Millennial And Gen Z Investors

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Inks Key Partnership, Advances Chip Development, Explores AI Datacenter Expansion

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Airship AI (NASDAQ: AISP) Marks Six Months On The NASDAQ: Russell 2000 Inclusion, Company Projects Triple-Digit Growth For 2024

The Future of Medicine: Key Biotech Stocks to Watch

Svenska lagar och regler - en inblick & rapport

Federated Indians of Graton Rancheria Supports California Governor Newsom’s Call to Halt Tribal Gaming Projects That Are Contrary to U.S. Department of Interior Precedent

Andrew Klein, M.D. named UNOS Chief Medical Officer